Baijin Life Science (HKG:1466) expects a loss of HK$100,000 for the year ended March 31, down from HK$8.5 million a year prior, a Thursday Hong Kong bourse filing said.
The jewelry business attributed the anticipated narrowing of loss mainly to a rise in revenue and gross profit, an increase in the reversal of allowances for expected credit losses on trade and other receivables, and higher other gains.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.